In March 2016, ARS signed an agreement with one of the biggest Russian pharmaceutical companies. This will be a Phase III, double blind, placebo controlled, randomized study of the efficacy and safety of a branded drug in patients with insomnia associated with increased nervous excitability.

ARS CRO will provide full range of clinical research services within the project: sites’ selection and administration, project management, clinical monitoring, safety reporting to local ethics committees, data management (eCRF) and statistics, final clinical study report writing, and others. 118 patients will be recruited at eight investigative sites in Russia.